Study guide

16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI

Board Certified Specialist in Renal Nutrition CSR

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Kidney Disease Foundations

1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk

2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment

2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry

3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools

3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss

4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History

4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment

5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality

5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment

6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning

6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances

7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients

7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy

8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy

8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)

9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients

9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD

10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support

10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support

11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities

11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure

12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends

12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories

13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics

13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence

14 Chapter 14: Domain 2 — Care Coordination, Communication & Education

14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support

15 Chapter 15: Domain 3 — Regulations & Quality Management

15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool

16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols

16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways

16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI

Key Takeaways Explain This Topic AI

KDIGO 2024 suggests 0.8 g protein/kg/day for adults with CKD G3–G5, avoiding more than 1.3 g/kg/day, and sodium below 2 g/day (below 5 g of salt).

KDIGO 2024 suggests considering drug treatment of metabolic acidosis when serum bicarbonate falls below about 18 mmol/L, without raising it above the upper limit of normal.

KDIGO 2017 CKD-MBD suggests lowering high phosphate toward normal, avoiding hypercalcemia, restricting calcium-based binders and keeping PTH about 2–9 times the upper limit in dialysis.

KDIGO 2026 anemia suggests IV iron in hemodialysis when ferritin is 500 ng/mL or less and TSAT is 30% or less, holding routine iron above ferritin 700 ng/mL or TSAT 40%, and ESAs before HIF-PH inhibitors.

KDIGO 2012 AKI suggests 20–30 kcal/kg/day and protein 0.8–1.0 g/kg without dialysis, 1.0–1.5 g/kg on kidney replacement therapy, and up to 1.7 g/kg on CRRT or when hypercatabolic.

Last updated: September 2026

KDIGO in brief

Kidney Disease: Improving Global Outcomes (KDIGO) is an international foundation that issues guidelines graded with the same system KDOQI uses: Level 1 "we recommend" or Level 2 "we suggest" , evidence A–D , plus ungraded practice points . The NKF's KDOQI program writes U.S. commentaries on KDIGO guidelines. The CDR reference list names many KDIGO documents and several NKF commentaries. The exam can therefore ask about a KDIGO number, a KDOQI number, or the difference between them.

CKD Evaluation and Management (2024)

Nutrition-relevant content:

Staging: cause, GFR category (G1–G5) and albuminuria category (A1–A3). Use race-free creatinine equations. Use cystatin C (eGFRcr-cys) when creatinine-based eGFR is less accurate or confirmation matters. Use validated risk equations (for example, the Kidney Failure Risk Equation) to estimate kidney-failure risk in G3–G5.

Diet: healthy, diverse diets with more plant-based and fewer ultra-processed foods (practice point). Renal dietitians should educate on sodium, phosphorus, potassium and protein, tailored to the person (practice point).

Protein: 0.8 g/kg/day for adults with CKD G3–G5 ( 2C ). Avoid more than 1.3 g/kg/day in people at risk of progression (practice point). Consider a very low-protein diet (0.3–0.4 g/kg/day) with essential amino acids or ketoacids (up to 0.6 g/kg/day) under supervision for willing people at risk of kidney failure. Never restrict protein in metabolically unstable people.

Sodium: below 2 g/day (below 90 mmol, or below 5 g of sodium chloride) ( 2C ).

Physical activity: at least 150 minutes per week of moderate activity, or as tolerated ( 1D ).

Metabolic acidosis: consider treatment, with or without dietary change, to prevent acidosis with clinical implications, for example bicarbonate below 18 mmol/L in adults. Do not raise bicarbonate above the upper limit of normal or harm BP, potassium or fluid status.

Hyperkalemia: use an individualized approach combining diet and medication, with renal dietitian assessment (practice point).

Kidney-protective drugs: RAAS blockade for albuminuria; SGLT2 inhibitors for many adults with CKD at eGFR 20 or above, including type 2 diabetes, heart failure or ACR of 200 mg/g or more ( 1A ); a nonsteroidal MRA for type 2 diabetes with albuminuria; GLP-1 receptor agonists for glycemic and cardiovascular benefit in type 2 diabetes.

CKD-Mineral and Bone Disorder (2017 update)

In G3a–G5D, lower elevated phosphate toward the normal range (2C) rather than treating to fixed numbers, and avoid hypercalcemia (2C).

Restrict the dose of calcium-based phosphate binders in adults (2B), and avoid long-term aluminum binders.

Limit dietary phosphate alone or with other treatments (2D), and consider the phosphate source (animal, vegetable or additives) when giving dietary advice.

Dialysate calcium of 1.25–1.50 mmol/L (2.5–3.0 mEq/L) in G5D (2C).

PTH in G5D: about 2–9 times the upper limit of normal for the assay (2C). Act on trends, not single values.

Calcitriol and vitamin D analogs are not routine in G3a–G5 not on dialysis. Reserve them for severe, progressive hyperparathyroidism in G4–G5.

Bone density testing to assess fracture risk if the result will change treatment.

KDIGO no longer recommends using the calcium × phosphorus product ; that <55 mg²/dL² target came from KDOQI 2003.

Anemia in CKD (2026 update, replacing 2012)

KDIGO published its updated anemia guideline in Kidney International 2026;109(1S):S1–S99.

Iron in HD: start iron if ferritin is 500 ng/mL or less and TSAT is 30% or less (2D). Prefer IV iron (2D), given proactively to keep iron status stable.

Iron in non-dialysis CKD and PD: start iron if ferritin is below 100 ng/mL with TSAT below 40%, or if ferritin is 100–300 ng/mL with TSAT below 25%. Use oral or IV iron based on preference and severity.

Withhold routine iron when ferritin is above 700 ng/mL or TSAT is 40% or higher (practice point).

Iron testing: every 3 months (non-dialysis and PD) and every 1–3 months (HD).

ESA first: use an ESA rather than a HIF-PH inhibitor as first-line treatment once correctable causes are addressed (2D). Avoid HIF-PH inhibitors in people at high risk, such as those with prior cardiovascular or thrombotic events or active cancer.

Start an ESA in G5D when hemoglobin is 9.0–10.0 g/dL or lower (2D). Aim below 11.5 g/dL during ESA maintenance ( 1D ).

Diabetes Management in CKD (2022)

HbA1c target individualized from below 6.5% to below 8.0% . Consider CGM or self-monitoring when HbA1c is unreliable.

Protein about 0.8 g/kg/day for diabetes with CKD not on dialysis. Sodium below 2 g/day. A diet rich in vegetables, fruits, whole grains, fiber, legumes and plant proteins.

Metformin when eGFR is 30 or above (dose-adjusted), an SGLT2 inhibitor when eGFR is 20 or above, and a GLP-1 RA when more glucose lowering is needed.

Blood pressure in CKD (2021)

A systolic target below 120 mmHg , when tolerated, using standardized office measurement, for adults with CKD not on dialysis (2B).

Sodium below 2 g/day and moderate physical activity.

Lipids in CKD (2013)

Statin or statin/ezetimibe for adults 50 or older with eGFR below 60 not on dialysis (1A).

Do not start statins in dialysis (2A), but continue existing therapy (2C). Statins are suggested for transplant recipients (2B).

Acute Kidney Injury (2012)

Energy 20–30 kcal/kg/day in any stage of AKI (2C).

Do not restrict protein to prevent or delay kidney replacement therapy (2D).

Protein: 0.8–1.0 g/kg/day in non-catabolic AKI without dialysis; 1.0–1.5 g/kg/day on KRT ; up to 1.7 g/kg/day on CRRT and in hypercatabolic patients (all 2D).

Enteral feeding is preferred (2C). Critical-care nutrition guidance (ASPEN/SCCM 2016) goes higher, up to 2.5 g/kg/day on frequent or continuous KRT.

Transplantation

The 2009 KDIGO transplant-recipient guideline covers lifestyle, lipids, diabetes, bone and infection after transplant.

The 2020 KDIGO candidate guideline covers pre-transplant evaluation, including obesity, frailty and nutrition.

Where KDOQI and KDIGO differ

Topic KDOQI 2020 (nutrition) KDIGO

Protein, CKD 3–5 without diabetes 0.55–0.60 g/kg/day (or VLPD 0.28–0.43 + ketoacids) 0.8 g/kg/day; avoid >1.3; VLPD 0.3–0.4 + ketoacids as a practice point (2024)

  • Protein, CKD with diabetes 0.6–0.8 g/kg/day About 0.8 g/kg/day (2022)
  • Sodium Below 2.3 g/day Below 2 g/day (2024, 2021, 2022)

Bicarbonate Keep at 24–26 mmol/L (OPINION) Consider treatment when below about 18 mmol/L; do not exceed normal (2024)

Phosphorus Keep serum phosphate in the normal range; consider bioavailability Lower elevated phosphate toward normal; restrict calcium binders (2017)

On the exam, read which source a question names. If none is named, choose the answer consistent with both sources, or the one the CDR reference list emphasizes for that topic (KDOQI 2020 for nutrition prescriptions).